A trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public trading debuts with more than $850 million
The FDA’s cancer drugs committee backs AstraZeneca’s Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
Johnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and
→ Boehringer Ingelheim has brought in Christie Bloomquist as SVP, corporate affairs, US human pharma, and she’ll be president of the Boehringer Cares Foundation. Peer
Axsome’s Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer’s disease to be approved by the FDA.
In its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral SERD camizestrant didn’t show a “clinically meaningful” benefit.
AstraZeneca touted …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844